RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Travere Therapeutics Stock

Travere Therapeutics P/S 2024

Travere Therapeutics P/S

2.51

Ticker

TVTX

ISIN

US89422G1076

WKN

A2QHYP

As of Aug 25, 2024, Travere Therapeutics's P/S ratio stood at 2.51, a -73.04% change from the 9.31 P/S ratio recorded in the previous year.

The Travere Therapeutics P/S history

Travere Therapeutics Aktienanalyse

What does Travere Therapeutics do?

Travere Therapeutics, Inc is a pharmaceutical company specializing in rare diseases. It was founded in 2019 and is headquartered in San Diego, California. Travere is tirelessly working to develop innovative therapies to improve the lives of patients with rare diseases. History Travere Therapeutics was formed from the merger of Retrophin, Inc and privately held company Censa Pharmaceuticals, Inc. Retrophin was founded in 2011 by Martin Shkreli and had difficulties in developing therapies for rare diseases. Shkreli later left the company and Retrophin focused on developing therapies for multiple rare diseases. In 2019, Retrophin merged with Censa Pharmaceuticals to form Travere Therapeutics, a company solely dedicated to rare diseases. Business Model Travere Therapeutics' business model is to develop innovative therapies for rare diseases that address an unmet medical need. With a strong focus on research and development, the company is working to discover, develop, and market new and life-changing therapies. Travere Therapeutics has a strong pipeline of drugs and medications in various stages of clinical development. This pipeline includes therapies for rare diseases such as nephrotic syndromes, mucopolysaccharidosis, lipid disorders, and others. Divisions Travere Therapeutics specializes in two business areas: pharmaceuticals and diagnostics. Pharmaceutical Business Travere Therapeutics' pharmaceutical business includes researching, developing, and marketing therapies for rare diseases. The company has a strong focus on research and development and has a pipeline of drugs and therapies aimed at improving the lives of patients with rare diseases. Diagnostics Business Travere Therapeutics' diagnostics business focuses on diagnostic tests for rare diseases. The company has partnerships with labs and facilities around the world specializing in diagnostics and genetics to ensure accurate diagnosis of patients with rare diseases. Products Travere Therapeutics offers a variety of products and therapies in different stages of development. Here are some of the key products the company offers: · Isturisa: a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of the hormone cortisol. · Re-PLAI: a medication for the treatment of nephrotic syndromes, a group of disorders caused by kidney dysfunction. · Enzyme Replacement Therapy (ERT): an approach to treating inherited metabolic disorders by administering missing enzymes. Conclusion Travere Therapeutics is an innovative company specializing in developing therapies for rare diseases. The company has a strong pipeline of drugs and the expertise to develop therapies for patients who are underserved by traditional medications. With a focus on research and diagnostics, the company has the potential to improve the lives of millions of patients with rare diseases. Travere Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Travere Therapeutics's P/S Ratio

Travere Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Travere Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Travere Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Travere Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Travere Therapeutics stock

What is the price-to-earnings ratio of Travere Therapeutics?

The price-earnings ratio of Travere Therapeutics is currently 2.51.

How has the price-earnings ratio of Travere Therapeutics changed compared to last year?

The price-to-earnings ratio of Travere Therapeutics has increased by -73.04% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Travere Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Travere Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Travere Therapeutics affect the company?

An increase in the price-earnings ratio of Travere Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Travere Therapeutics affect the company?

A decrease in the price-earnings ratio of Travere Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Travere Therapeutics?

Some factors that influence the price-earnings ratio of Travere Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Travere Therapeutics pay?

Over the past 12 months, Travere Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Travere Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Travere Therapeutics?

The current dividend yield of Travere Therapeutics is .

When does Travere Therapeutics pay dividends?

Travere Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Travere Therapeutics?

Travere Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Travere Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Travere Therapeutics located?

Travere Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Travere Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Travere Therapeutics from 8/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/25/2024.

When did Travere Therapeutics pay the last dividend?

The last dividend was paid out on 8/25/2024.

What was the dividend of Travere Therapeutics in the year 2023?

In the year 2023, Travere Therapeutics distributed 0 USD as dividends.

In which currency does Travere Therapeutics pay out the dividend?

The dividends of Travere Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Travere Therapeutics

Our stock analysis for Travere Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Travere Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.